Actinium Pharmaceuticals Business Summary

Actinium Pharmaceuticals, Inc. (ATNM) is a late-stage biopharmaceutical company specializing in Targeted Alpha Therapy (TAT) to treat advanced cancers. The company generates revenue primarily through strategic licensing agreements, research collaborations, and milestone payments, though it remains in a pre-commercial clinical phase with minimal trailing revenue. Its business is segmented into targeted conditioning agents, led by Iomab-B for bone marrow transplant preparation, and therapeutic candidates like Actimab-A for acute myeloid leukemia (AML) and ATNM-400 for solid tumors. Actinium differentiates itself through its proprietary Antibody Warhead Enabling (AWE) platform and a cyclotron-based manufacturing process for the potent alpha-emitter Actinium-225. It competes directly with major radiopharmaceutical players such as Novartis, Bayer, and Fusion Pharmaceuticals (AstraZeneca), positioning itself as a specialized leader in hematology-focused alpha therapies and next-generation conditioning. Originally incorporated in 2000 as a subsidiary of Antigenics Inc. (now Agenus), Actinium is currently led by Chairman and CEO Sandesh Seth, who has over 25 years of experience in investment banking at firms like Laidlaw & Co. and Cowen, alongside a pharmaceutical background at Pfizer and Warner-Lambert. Following the February 2026 resignation of CFO Steve O’Loughlin, Seth also serves as the company's Principal Financial Officer. The leadership team includes Chief Strategy Officer Jenny Hsieh and Chief Business Officer Lynn Bodarky, who drive corporate development and market access. The company’s board of directors features high-pedigree industry veterans, including Lead Independent Director C. David Nicholson (formerly of Allergan and Bayer), Ajit Shetty (former Head of Enterprise Supply Chain at Johnson & Johnson), and June Almenoff (former President and CMO of Furiex Pharmaceuticals).